Curated News
By: NewsRamp Editorial Staff
May 08, 2025
Clene Announces Promising Results for CNM-Au8 Program in ALS and MS
TLDR
- Clene announced progress on CNM-Au8 program for ALS and MS, positioning for potential NDA submission, showcasing survival benefits, enhancing competitiveness.
- CNM-Au8 therapy targets mitochondrial function, NAD pathway, and reduces oxidative stress, leading to improved neuronal function and survival in ALS and MS patients.
- Clene's CNM-Au8 program offers hope for ALS and MS patients by enhancing survival, remyelination, and neuronal repair, aiming to improve quality of life.
- Exciting data from Clene's Phase 2 extension shows promising results in improving survival and neuronal repair, offering new possibilities for ALS and MS treatment.
Impact - Why it Matters
This news matters as it highlights Clene's advancements in developing potential treatments for ALS and MS, offering hope to patients with these neurodegenerative diseases. The positive results and progress on the CNM-Au8 program indicate a promising future for the company and potential improved outcomes for individuals suffering from ALS and MS.
Summary
Clene (NASDAQ: CLNN) announced first quarter 2025 financial results and progress on its CNM-Au8 program for ALS and MS. The company is preparing for a potential NDA submission under the FDA’s Accelerated Approval pathway for ALS in Q4 2025, supported by survival data and upcoming biomarker analysis. New data also showed CNM-Au8 significantly improved survival in patients with more severe ALS. In MS, Clene presented Phase 2 extension results demonstrating remyelination and neuronal repair. The company reported a Q1 net loss of $0.8 million on reduced expenses and $9.8 million in cash, funding operations into Q3 2025.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Announces Promising Results for CNM-Au8 Program in ALS and MS
